Trial Profile
A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects With Type 1 Diabetes Mellitus, and Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Insulin lispro (Primary) ; MK-1092 (Primary) ; Glucose; Insulin glargine
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 07 Apr 2022 Results published in the Clinical Pharmacology and Therapeutics
- 16 Jun 2020 Results assessing the safety and tolerability of single subcutaneous (SC) doses of MK-1092 in T1DM and T2DM, were presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association